No Detail Found!

Glucagon-like peptide 1 and its association with dipeptidyl peptidase IV in subjects with various degrees of glucose tolerance

Author(s)
Ruqaya Department of Physiology, Baqai Medical University,Karachi,Pakistan
Mohammad Saleh Soomro Department of Physiology, Baqai Medical University,Karachi,Pakistan
Nazish Waris Baqai Institute of Diabetology and Endocrinology,Karachi,Pakistan
Iftikhar Ahmed Siddiqui Department of Biochemistry, Baqai Medical University,Karachi,Pakistan
Asher Fawwad Department of Biochemistry, Baqai Medical University,Karachi,Pakistan
Abdul Basit Baqai Institute of Diabetology and Endocrinology,Karachi,Pakistan
Abstract
Dipeptidyl peptidase IV (DPP-4) and Glucagon like peptide 1 (GLP-1) has profound effect on insulin and glucagon secretion; ultimately decreasing glucose levels. We find out the association of GLP-1 levels and DPP-4 in normal, impaired and newly diagnose type 2 diabetic glucose tolerance. Prospective case control study was conducted at Department of Physiology, Baqai Medical University by the collaboration of Baqai Institute of Diabetology and Endocrinology; Karachi-Pakistan. Study groups were categorized into three groups Control, Impaired glucose tolerant (IGT) and newly diagnose type 2 diabetes mellitus (NDD). Biochemical parameters were estimated by international standard protocols. Logistic regression analysis and Chi square test with statistical significance at p value <0.05 were applied. DPP-4 concentrations were significantly lower in NDD participants compared to control and IGT participants (p=0.01), whereas GLP-1 levels were significantly higher in Control than Impaired glucose tolerant and NDD (p = 0.013). GLP1 levels and SBP were also found to be positively correlated with serum DPP4 levels in NDD group (p<0.05). GLP1 and DPP4 levels in NDD group (p<0.05) and in controls (p<0.001) respectively showed strong significant positive correlation. Effective correlation between GLP1 and DPP4 was found as both contribute to control hyperglycemia in NDD and impaired glucose tolerant people.
Publication Details
Page(s) 2773-2778
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: SUP6, Year: 2020

Request the full text from PASTIC

Keywords
newly diagnose Type 2 diabetes (NDD), glucagon-like peptide 1(GLP1), Dipeptidyl peptidase IV (DPP-4)
References
. .obese subjects and their association with insulin resistance. Clin. Biochem, 50 : 746-749.
Altenhofen D,da Luz G,Frederico MJ,Venzke D,Brich M,Vigil S,Frode TS,Linares CE,Pizzolatti MG,Silva FR .2017 .Bis-pyrano prenyl isoflavone improves glucose homeostasis by inhibiting dipeptidyl peptidase-4 in hyperglycemic rats. J. Cell Biochem, 118(1) : 92-103.
Anandhakrishnan A,Korbonits M .2016 .Glucagonlike peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World J. Diabetes, 7(20) : 572-598.
Bakris GL .2016 .The implications of blood pressure measurement methods on treatment targets for blood pressure. , 134(13) : 904-905.
Bastin M and Andreelli F .2019 .Dual GIP-GLP1- Receptor Agonists in The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential. Diabetes Metab. Syndr. Obes., 12 : 1973-1985.
Chia CW,Egan JM,Ferrucci L JM .2018 .Age-related changes in glucose metabolism hyperglycemia and cardiovascular risk. Circ. Res., 123(7) : 886-904.
Fawwad A,Sabir R,Riaz M,Moin H,Basit A .2016 .Measured versus calculated LDL-cholesterol in subjects with type 2 diabetes. Pak. J. Med. Sci., 32(4) : 955-960.
Gluvic Z,Zaric B,Resanovic I,Obradovic M,Mitrovic A,Radak D,Isenovic ER D .2017 .Link between Metabolic Syndrome and Insulin Resistance. Curr. Vasc. Pharmacol., 5(1) : 30-39.
Gupta S and Bansal S .2020 .Does a rise in BMI cause an increased risk of diabetes?: Evidence from India. Plos One, 15(4) : 1-20.
Holst JJ,Gribble F,Horowitz M,Rayner CK M .2016 .Roles of the gut in glucose homeostasis. Diabetes Care, 39(6) : 884-892.
Janzen KM,Steuber TD,Nisly SA .2016 .GLP-1 agonists in Type 1 diabetes mellitus. Ann Pharmacother, 50(8) : 656-65.
Liu X,Men P,Wang Y,Zhai S,Liu G .2016 .Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: A meta-analysis. Lipids in Health and Disease, 15(1) : 204-212.
Lund A,Bagger JI,Wewer Albrechtsen NJ,Christensen M,Grøndahl M,Hartmann B,Mathiesen ER,Storkholm CP,van Hall JH,Rehfeld G,Hornburg JF,Meissner D,Mann F,Larsen M,Holst S,Lauritsen JJ,Knop TV,FK TV .2016 .Evidence of extrapancreatic glucagon secretion in man. Diabetes, 65(3) : 585-597.
Mak WY,Nagarajah JR,Abdul Halim H,Ramadas A,Mohd Pauzi Z,Pee LT,Jagan N LT .2020 .Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital. J. Pharm. Policy. Pract, 13(1) : 34-41.
McShane LM,Irwin N,O'Flynn D,Franklin ZJ,Hewage CM,O'Harte FP CM .2016 .Glucagon receptor antagonist and GIP agonist combination for dietinduced obese mice. J. Endocrinol., 229(3) : 319-330.
Mirosevic G,Blaslov K,Naranda F,Plecko M,Radosevic JM,Vrkljan M JM .2017 .The emerging role of incretins in the pathophysiology of insulin resistance in type 1 diabetes, 3(3. , : 90-96.
Nargis T,Kumar K,Ghosh AR,Sharma A,Rudra D,Sen D,Chakrabarti S,Mukhopadhyay S,Ganguly D,Chakrabarti P .2017 .KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes. Mol. Metab, 6(11) : 1529-1539.
Nauck M .2016 .Incretin therapies: Highlighting common features and differences in the modes of action of glucagonlike peptide1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. , 18(3) : 203-216.
Nauck MA,Meier JJ,Cavender MA,Abd El Aziz M and Drucker DJ MA .2017 .Cardiovascular actions and clinical outcomes with glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. , 136(9) : 849-870.
Nauck MA,Meier JJ .2018 .Incretin hormones: Their role in health and disease. Diabetes Obes. Metab., 20(S1) : 5-21.
Neidert LE,Wainright KS,Zheng C,Babu JR,Kluess HA .2016 .Plasma dipeptidyl peptidase IV activity and measures of body composition in apparently healthy people. Heliyon, 2(4) : e00097.
Ormazabal V,Nair S,Elfeky O,Aguayo C,Salomon C,Zuñiga FA C .2018 .Association between insulin resistance and the development of cardiovascular disease. Cardiovasc. Diabetol., 17(1) : 122-235.
Ottobelli ,Chielle E,de Souza WM,da Silva TP,Moresco RN,Moretto MB .2016 .Adipocytokines inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects. Clin. Biochem, 49(7-8) : 548-553.
Ramesh ,Gupta DD .2018 .Role of DPP-4 inhibitors in the management of type 2 diabetes. Int. J. Basic Clin. Pharmacol, 7(12) : 2488-2495.
Sanchez-Garrido MA,Brandt SJ,Clemmensen C,Muller TD,DiMarchi RD,Tschop MH .2017 .GLP1/glucagon receptor co-agonism for treatment of obesity. Diabetologia, 60(10) : 1851-1861.
Sarkar J,Nargis T,Tantia O,Ghosh S,Chakrabarti P .2019 .Increased plasma dipeptidyl peptidase-4 (DPP4) activity is an obesity-independent parameter for glycemic deregulation in Type 2 diabetes patients. Front. Endocrinol., 10 : 505-511.
Senyigit A,Tabak O,Orhanoglu T,Karadag A .2017 .Glucagon-like peptide-1 levels and dipeptidyl peptidase-4 activity in type 2 diabetes. Clin. Invest. med, 40(5) : 188-199.
Sharma SP,Ajankar AP,Kale A .2017 .Comparison of glucose levels using glucometer and GOD-POD Method in diabetic patients. Int. J. Clin. Biochem and Res., 4(1) : 6-10.
Silva Junior WS,Souza M,Das GC,Nogueira Neto JF,Bouskela E,Kraemer-Aguiar LG .2019 .Dipeptidyl Peptidase 4 Activity Is Related to Body Composition, Measures of Adiposity and Insulin Resistance in Subjects with Excessive Adiposity and Different Degrees of Glucose Tolerance. J. Diabetes Res., : 1-8.
Tanaka S,Kanazawa I,Notsu M,Sugimoto T .2016 .Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus. Diabetes Res. Clin. Pract, 116 : 1-6.
Togashi Y,Shirakawa J,Okuyama T,Yamazaki S,Kyohara M,Miyazawa A,Terauchi Y .2016 .Evaluation of the appropriateness of using glucometers for measuring the blood glucose levels in mice. Sci. Rep, 6(1) : 1-9.
Valerio CM,de Almeida JS,Moreira RO,Aguiar LBS,Siciliano PO,Carvalho DP,Godoy-Matos AF,Diabetol AF .2017 .Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2. , 9 : 26-30.
Zheng T,Chen B,Yang L,Zhang X,Liu H,Qin L .2017 .Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese population. Metabolism, 73 : 125-134.
Zilleßen P,Celner J,Kretschmann A,Pfeifer A,Racké K,Mayer P K .2016 .Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes. Sci. Rep, 6 : 1-9.
0

Citations

0

Downloads

13

Views